Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.54)
# 285
Out of 5,148 analysts
121
Total ratings
52.88%
Success rate
28.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $140 | $90.23 | +55.16% | 11 | Mar 2, 2026 | |
| NGNE Neurogene | Initiates: Buy | $200 | $22.39 | +793.26% | 1 | Feb 27, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $98 → $104 | $59.24 | +75.57% | 10 | Feb 26, 2026 | |
| BEAM Beam Therapeutics | Initiates: Buy | $74 | $27.89 | +165.33% | 1 | Feb 20, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $128 → $79 | $22.30 | +254.26% | 10 | Feb 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $411 → $441 | $475.52 | -7.26% | 10 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $415 → $429 | $321.08 | +33.61% | 10 | Feb 17, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $40 → $43 | $13.62 | +215.71% | 3 | Feb 3, 2026 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $6 → $5 | $0.55 | +808.93% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $148 → $204 | $135.39 | +50.68% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $0.50 | +1,500.96% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $67 | $8.45 | +692.90% | 7 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $4.58 | +206.01% | 11 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $4.87 | +105.34% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $13.83 | +290.60% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $7.90 | +735.44% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $15.92 | +842.21% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $148.60 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $9.33 | +2,472.35% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
Mar 2, 2026
Maintains: Buy
Price Target: $141 → $140
Current: $90.23
Upside: +55.16%
Neurogene
Feb 27, 2026
Initiates: Buy
Price Target: $200
Current: $22.39
Upside: +793.26%
BioMarin Pharmaceutical
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $104
Current: $59.24
Upside: +75.57%
Beam Therapeutics
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $27.89
Upside: +165.33%
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $22.30
Upside: +254.26%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Hold
Price Target: $411 → $441
Current: $475.52
Upside: -7.26%
Alnylam Pharmaceuticals
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $321.08
Upside: +33.61%
Wave Life Sciences
Feb 3, 2026
Maintains: Buy
Price Target: $40 → $43
Current: $13.62
Upside: +215.71%
Tenaya Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.55
Upside: +808.93%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $135.39
Upside: +50.68%
Nov 21, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $0.50
Upside: +1,500.96%
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $8.45
Upside: +692.90%
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.58
Upside: +206.01%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $4.87
Upside: +105.34%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $13.83
Upside: +290.60%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $7.90
Upside: +735.44%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $15.92
Upside: +842.21%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $148.60
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $9.33
Upside: +2,472.35%